Report Overview

The US Fabry disease drugs market size stood at USD 1.1 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Fabry disease is a rare X-linked lysosomal storage disorder with a deficiency of alpha-galactosidase enzyme resulting in progressive organ dysfunction. This disease is caused by an abnormal build-up of a specific fatty matter called globotriaosylceramide in multiple tissues of the body including eyes, skin, kidney, gastrointestinal system, brain, heart, and central nervous system.



Market Drivers

Growing demand for messenger RNA as a treatment modality for Fabry disease is boosting the market growth. The rising adoption of the treatment is mostly witnessed in the countries that have higher ratio of patients diagnosed with Fabry disease. For instance, according to the estimates provided by Census Bureaus population, in the U.S. around 3,800 males are suffering from Fabry disease. Hence, the adoption of these novel treatments to mitigate or remove the disease is witnessing a significant market growth over the forecast period.

However, lack of awareness about advancements with respect to treatments for Fabry disease and limitations in adopting new technologies in certain countries owing to inadequate financial support from the respective government is hampering the adoption of the novel treatment and may hinder the market in the upcoming years.